Biocon Biologics has expanded its footprint in Malaysia, delivering 100 million insulin cartridges to the country’s Ministry of Health since entering the market in 2016. The company’s integrated manufacturing facility in Johor has seen a cumulative investment of $600 million since 2011.
Susheel Umesh, Chief Commercial Officer, Biocon Biologics, said: “Expanding access to over 345,000 diabetes patients in Malaysia by providing over 100 million cartridges of rh-insulin reinforces our commitment to equitable diabetes care. Our partnership with the Malaysian Ministry of Health and Duopharma underlines how local manufacturing and global expertise can come together to create scalable, sustainable healthcare solutions for patients.”
Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Limited, has commercialised nine biosimilars from its portfolio which are addressing patients’ needs in key emerging markets and advanced markets like the U.S, Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases.